Quantcast

Latest glioblastoma Stories

2014-10-20 23:02:05

In-demand research report “Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the APAC glioblastoma multiforme therapeutics market is predicted to reach USD 105.8 million by 2020. London, UK (PRWEB) October 20, 2014 The glioblastoma multiforme (GBM) therapeutics market in the APAC...

2014-10-17 23:08:13

NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has received a $1Million grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma, (NCI Phase II SBIR, R44CA144817 - 02A1)". Tucson, AZ (PRWEB) October 17, 2014 NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has received a $1Million grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of...

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-08-12 08:30:58

SAN FRANCISCO, Aug. 12, 2014 /PRNewswire-iReach/ -- OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor. (Photo: http://photos.prnewswire.com/prnh/20140811/135194) OS2966 is a first in class therapeutic being investigated in...

2014-07-07 10:11:17

McGill University Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. The SUMO family proteins modify other proteins and the SUMOylation of proteins are critical for many cellular processes. Identifying SUMO’s role in the cancer cell...

2014-06-15 14:59:20

Broad Institute of MIT and Harvard Cellular makeup of glioblastoma more diverse than previously thought Scientists from the Broad Institute and Massachusetts General Hospital (MGH) have conducted a first-of-its-kind study that characterizes the cellular diversity within glioblastoma tumors from patients. The study, which looked at the expression of thousands of genes in individual cells from patient tumors, revealed that the cellular makeup of each tumor is more heterogeneous than...

2014-06-01 08:20:27

Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-29 04:21:52

ROCKLAND, Massachusetts, May 29, 2014 /PRNewswire/ -- ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine EMD Serono pipeline products across oncology and immuno-oncology to be presented, including anti-PD-L1, c-Met...

2014-05-19 08:28:02

A registry of 457 recurrent glioblastoma patients shows that patients treated commercially with NovoTTF Therapy in 2012 and 2013 achieved the longest median overall survival yet shown in non-experimental use for patients with recurrent glioblastoma NEW YORK, May 19, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that an analysis of the efficacy and safety data from its U.S. patient registry will be published as part of the 50(th) meeting of the...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin